首页|Drug-interaction between paclitaxel and goshajinkigan extract and its constituents
Drug-interaction between paclitaxel and goshajinkigan extract and its constituents
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Springer Nature
Paclitaxel, a standard chemotherapeutic agent for several types of cancer, including ovarian, breast, and non-small-cell lung cancer, causes peripheral neuropathy as an adverse effect in 60-70% of the patients. The utility of combination therapy with paclitaxel and goshajinkigan, a traditional Japanese Kampo medicine, in managing paclitaxel-induced neuropathy during chemotherapy has been explored. Paclitaxel is predominantly metabolized in the liver by cytochrome P450 (CYP) 2C8 to produce 6 alpha-hydroxypaclitaxel and by CYP3A4 to produce 3 '-p-hydroxypaclitaxel. In this study, we evaluated the inhibitory or inducing effects of goshajinkigan extract (GJG) and its representative and bioavailable constituents, geniposidic acid, plantagoguanidinic acid, paeoniflorin, catalpol, loganin, and neoline, on the metabolism of paclitaxel via CYP2C8 and CYP3A4 using pooled human liver microsomes and cultured human cryopreserved hepatocytes to provide the drug information about the pharmacokinetic interaction of this combination therapy. GJG significantly inhibited the production of 3'-p-hydroxypaclitaxel and 6 alpha-hydroxypaclitaxel in vitro in a concentration-dependent manner. The half maximal inhibitory concentration (IC50) values of GJG were 4.5 and 7.8 mg/ml, respectively, for 3 '-p-hydroxypaclitaxel and 6 alpha-hydroxypaclitaxel productions. Neoline inhibited the production of 3 '-p-hydroxypaclitaxel at 50 mu M, but not at lower concentrations. Apart from neoline, other GJG constituents (at concentrations up to 50 or 10 mu M of all test substances) did not exhibit inhibitory or inducing effects. Since GJG showed the inhibitory effect on the metabolism of paclitaxel at much higher concentrations than those used clinically, it can be concluded that GJG product does not exhibit any pharmacokinetic interaction with paclitaxel in clinical practice. [GRAPHICS] .
NSTL
Springer Nature
